At 8:57 a.m. Eastern, CNBC Squawk Box did not tee up a thought experiment. It put a live wire on the desk. The segment was titled the future of AI doctors, but the subtext was simpler and sharper. What happens when software is no longer advising medicine but legally participating in it. Doctronic, founded in New York in May 2024, walked straight into that question with receipts, not hypotheticals.
Matt Pavelle and Dr. Adam Oskowitz, co-founders and co-CEOs of Doctronic, came on air days after Utah approved the first state-backed pilot allowing an AI system to renew routine prescriptions. Not suggest. Not draft. Renew. One hundred ninety one low-risk medications. Four dollars per renewal. Human physicians reviewing the first two hundred fifty prescriptions in each class, then letting the system run. No narcotics. No theatrics. Just policy, code, and consequence lining up in real time.
The problem they framed was not futuristic. It was painfully current. It takes an average of twenty six days to see a primary care physician in the United States. Medication non-adherence kills an estimated one hundred fifty thousand people a year. Thirty to forty percent of that is friction. Missed appointments. Lost refills. Paperwork masquerading as safety. Doctronic’s AI processes a renewal end to end in under thirty minutes, escalating only when uncertainty appears. Dr. Adam Oskowitz was blunt. The system checks more variables, more consistently, than a rushed human ever could in a ten minute visit.
This was not a garage demo. Doctronic has logged seventeen million AI consultations, scaled to roughly one hundred fifty thousand visits a week, and validated its clinical approach with ninety nine point two percent treatment alignment against physicians. Lightspeed Venture Partners led a twenty million dollar Series A after a five million dollar seed, backed by Union Square Ventures and angels like Dr. Fei-Fei Li. CNBC did not host a moonshot. It hosted infrastructure announcing itself.
There is wordplay baked into the name Doctronic for a reason. This is medicine moving from episodic to electric. Always on. Always checking. Less white coat, more circuit breaker. Utah’s regulatory sandbox did not bless hype. It tested mechanics. The market is watching whether this current holds or trips the system.
